Efficacy and safety of oral fludarabine/cyclophosphamide regimen in previously treated indolent lymphomas [1]

Leukemia and Lymphoma

Volumn 46, Issue 12, 2005, Pages 1839-1841

  Stefoni, Vittorio ^a   Alinari, Lapo ^a   Musuraca, Gerardo ^a   Tani, Monica ^a   Marchi, Enrica ^a   Gabriele, Annalisa ^a   Fina, Mariapaola ^a   Pileri, Stefano ^a   Baccarani, Michele ^a   Zinzani, Pier Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; FLUDARABINE; PURINE DERIVATIVE;

ADULT; AGED; B CELL LYMPHOMA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEART DISEASE; HUMAN; KIDNEY DISEASE; LETTER; LIVER DISEASE; MALE; NAUSEA AND VOMITING; NEUTROPENIA; PNEUMOCYSTOSIS; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADMINISTRATION, ORAL; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASM STAGING; TIME FACTORS; TREATMENT OUTCOME; VIDARABINE;

EID: 32144435222     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500264421     Document Type: Letter

References (12)

1. Zinzani, P and Magagnoli, M and Moretti, L and De Renzo, A and Battista, R and Zaccaria, A and Guardiani, L and Mazza, P and Marra, R and Ronconi, F and Lauta, V and Bendandi, M and Gherlinzoni, F and Gentilini, P and Ciccone, F and Cellini, C and Stefoni, V and Ricciuti, F and Gobbi, M and Tura, S. (2000) Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma Journal of Clinical Oncology, 18, pp. 773 - 779.
2. Solal-Celigny, P and Brice, P and Brousse, N and Caspard, H and Bastion, Y and Haioun, C and Bosly, A and Tilly, H and Bordessoule, D and Sebban, C and Harousseau, J and Morel, P and Dupas, B and Plassart, F and Vasile, N and Fort, N and Leporrier, M. (1996) Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: A multicenter study by the Group d'Etude des Lymphomes de l'Adulte Journal of Clinical Oncology, 14, pp. 514 - 519.
3. Zinzani, P and Pulsoni, A and Pernotti, A and Soverini, S and Zaja, F and De Renzo, A and Storti, S and Lauta, V and Guardigli, L and Gentilini, P and Tucci, A and Molinari, A and Gobbi, M and Falini, B and Fattori, P and Ciccone, F and Alinari, L and Martelli, M and Pileri, S and Tura, S and Baccarani, M. (2004) Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma Journal of Clinical Oncology, 22, pp. 2654 - 2661.
4. Zinzani, P and Bendandi, M and Magagnoli, M and Gherlinzoni, F and Merla, E and Tura, S. (1997) Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma Annals of Oncology, 8, pp. 379 - 383.
5. Boogaerts, M and Van Hoof, A and Catovsky, D and Kovacs, M and Montillo, M and Zinzani, P and Binet, J and Feremans, W and Marcus, R and Bosch, F and Verhoef, G and Klein, M. (2001) Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia Journal of Clinical Oncology, 19, pp. 4252 - 4258.
6. Rossi, J and Van Hoof, A and de Boeck, K and Johnson, S and Bron, D and Foussard, C and Lister, T and Berthou, C and Kramer, M and Littlewood, T and Marcus, R and Deconinck, E and Montillo, M and Guibon, O and Tollerfield, S. (2004) Efficacy and safety of oral fludarabine phosphate in previously untreated patients with chronic lymphocytic leukemia Journal of Clinical Oncology, 22, pp. 1260 - 1267.
7. Carbone, P and Kaplan, H and Musshoff, K and Smithers, D and Tubiana, M. (1971) Report of the committee on Hodgkin's disease staging classification Cancer Research, 31, pp. 1860 - 1861.
8. Harris, N and Jaffe, E and Stein, H and Banks, P and Chan, J and Cleary, M and Delsol, G and De Wolf-Peeters, C and Falini, B and Gatter, K. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Study Group Blood, 84, pp. 1361 - 1392.
9. Cheson, B and Horning, S and Coiffier, B and Shipp, M and Fisher, R and Connors, J and Lister, T and Vose, J and Grillo-Lopez, A and Hagenbeek, A and Cabanillas, F and Klippensten, D and Hiddemann, W and Castellino, R and Harris, N and Armitage, J and Carter, W and Hoppe, R and Canellos, G. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas Journal of Clinical Oncology, 17, pp. 1244 - 1253. NCI Sponsored International Working Group
10. Klasa, R and Meyer, R and Shustik, C and Sawka, C and Smith, A and Guevin, R and Maksymiuk, A and Rubinger, M and Samosh, M and Laplante, S and Grenier, J. (2002) Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen Journal of Clinical Oncology, 20, pp. 4649 - 4654.
11. Hochster, H and Oken, M and Winter, J and Gordon, L and Raphael, B and Bennett, J and Cassileth, P. (2000) Phase I study of fludarabine plus cyclophosphamide in patients with previously untreated low-grade lymphoma: Results and long-term follow-up - a report from the Eastern Cooperative Oncology Group Journal of Clinical Oncology, 18, pp. 987 - 994.
12. Santini, G and Nati, S and Spriano, M and Gallamini, A and Pierluigi, D and Congiu, A and Truini, M and Rubagotti, A and Chisesi, T and Vimercati, R and Rossi, E and Sertoli, M and Mattei, D and Marino, G and Gobbi, M. (2001) Fludarabine in combination with cyclophosphamide or with cyclophosphamide plus mitoxantrone for relapsed or refractory low-grade non-Hodgkin's lymphoma Haematologica, 86, pp. 282 - 286.